SIRPA and neoplasm: We rationalized that engineering NDV to express an anti-CD47 monoclonal antibody or a SIRPα-Fc immunoadhesin would enable localized delivery of CD47-blocking agents to the tumor microenvironment, thereby enhancing therapeutic specificity while minimizing on-target, off-tumor effects.